BMI Cutoff Comparison: Minimum Eligibility Across 12 Platforms

"Do I qualify for a GLP-1?" is one of the most common questions in weight loss telehealth. The answer depends on which provider you ask — because while there are FDA-approved eligibility criteria, not every provider applies them identically.

We surveyed 12 GLP-1 telehealth platforms to map their eligibility requirements: BMI thresholds, qualifying comorbidities, and any additional restrictions.

The FDA-Approved Eligibility Standard

For FDA-approved GLP-1 medications (Wegovy, Zepbound), the labeled indication for weight management is:

• BMI ≥30 (obesity), OR
• BMI ≥27 (overweight) with at least one weight-related comorbidity: Type 2 diabetes, hypertension, dyslipidemia (high cholesterol), or obstructive sleep apnea

This is the baseline. Providers prescribing FDA-approved medications typically follow these criteria. Providers prescribing compounded medications have more clinical discretion since compounded products are prescribed off the FDA-approved label.

BMI Eligibility by Provider

*Many compounded-medication providers use "clinician discretion" for BMI borderline cases (27–30 without documented comorbidities). This means a prescribing clinician evaluates your full health picture rather than applying a rigid BMI cutoff.

The BMI Debate in 2026

BMI is an imperfect screening tool. It doesn't account for muscle mass, bone density, fat distribution, or metabolic health. A 5'10" person at 210 lbs has a BMI of ~30 whether they're a sedentary office worker with metabolic syndrome or a recreational athlete with higher muscle mass.

The medical community is increasingly moving away from BMI as the sole eligibility criterion for weight management treatment. The American Medical Association adopted a policy in 2023 recognizing BMI's limitations. Some GLP-1 providers have followed suit, using BMI as one factor among several rather than a hard gatekeeping threshold.

Qualifying Comorbidities: What Counts

For the BMI 27–29.9 range, you typically need at least one qualifying comorbidity. The most commonly accepted:

• Always qualifies: Type 2 diabetes, hypertension (high blood pressure), dyslipidemia (high cholesterol/triglycerides), obstructive sleep apnea
• Usually qualifies: Prediabetes, PCOS (polycystic ovary syndrome), non-alcoholic fatty liver disease, osteoarthritis
• Sometimes qualifies: GERD, depression/anxiety related to weight, joint pain, cardiovascular disease

If you have a comorbidity that's not on the standard list, it's worth completing the intake process anyway. Clinicians have discretion to assess whether your overall health picture warrants treatment, even if your specific condition isn't on the "standard" list.

What If Your BMI Is Below 27?

If your BMI is below 27, you're unlikely to qualify for FDA-approved GLP-1 medications through any legitimate provider. Some compounded-medication providers may have lower thresholds based on individual clinician assessment, but prescribing GLP-1s to patients at a healthy weight raises legitimate safety and ethical questions.

If your BMI is 25–27, focus on whether you have weight-related health conditions that might warrant treatment. If your BMI is below 25, GLP-1 medications are not indicated for weight loss, and any provider willing to prescribe them at this BMI should be approached with caution.

The Bottom Line

If your BMI is 30+, you'll qualify with essentially every legitimate provider. If your BMI is 27–30, you'll qualify with most providers if you have a qualifying comorbidity. The fastest way to find out is to complete an intake questionnaire — most providers offer this for free and will tell you within 24–48 hours whether you're eligible.